On the list of dreaded medical tests, a prostate biopsy probably ranks fairly high. The common procedure requires sticking a needle into the prostate gland to remove tissue for assessment. Thousands of men who undergo the uncomfortable procedure, prompted by a positive PSA (prostate-specific antigen) test, ultimately don’t require cancer treatment. Today, scientists report progress toward minimizing unnecessary biopsies: They have identified the molecules likely responsible for the scent of prostate cancer, which could be detected by chemically “sniffing” urine.
The researchers will present their results today at the 253rd National Meeting & Exposition of the American Chemical Society (ACS). ACS, the world’s largest scientific society, is holding the meeting here through Thursday. It features more than 14,000 presentations on a wide range of science topics.
“The idea for this project started with a study published in 2014 showing that trained canines could detect prostate cancer with greater than 97 percent accuracy,” says Mangilal Agarwal, Ph.D., the project’s principal investigator. His team had already been working on a sensor to sniff hypoglycemia on a person’s breath as dogs have also been shown to do. When the prostate cancer study appeared in the Journal of Urology, Agarwal’s lab set out to determine what molecules the dogs might be sensing.
“If dogs can smell prostate cancer, we should be able to, too,” says Amanda Siegel, Ph.D., who is presenting the work at the meeting. Both Agarwal and Siegel are at the Integrated Nanosystems Development Institute of Indiana University-Purdue University Indianapolis (IUPUI) and the Richard L. Roudebush VA Medical Center.
Prostate cancer is the third most common type of cancer in the United States. In 2016, more than 180,000 new cases were diagnosed, according to the U.S. National Institutes of Health’s National Cancer Institute. Early detection has been critical to saving the lives of many men with prostate cancer. But diagnosing the disease can be fraught with challenges.
The screening test that doctors use now to determine whether to perform a biopsy assesses PSA levels in a blood sample. The prostate gland normally produces this protein in small amounts. Increased levels, however, can indicate many different conditions besides cancer, including prostate infection. As a result, the test is widely recognized as flawed and often leads to unnecessary biopsies.
“Currently, about 60 percent of men who get a biopsy to test for prostate cancer don’t need to get one,” Siegel says. “We hope our research will help doctors and patients make better-informed decisions about whether to have a biopsy, and to avoid unwarranted procedures.”
To determine which molecules wafting from urine could indicate prostate cancer in a patient, the IUPUI and VA team collected urine samples from 100 men undergoing prostate biopsies. To avoid issues that similar studies have had with sample degradation, Agarwal’s team developed a pre-processing step — adding sodium chloride and neutralizing the pH — to ensure the samples would remain intact during the analysis. Then, they used gas chromatography-mass spectrometry to identify the volatile organic compounds floating in the “headspace” above the urine samples. With this method, the researchers pinpointed a small set of molecules that showed up in 90 percent of the samples from patients with prostate cancer but not in samples from those who did not have the disease.
Next, the team plans to conduct large-scale tests at multiple health centers to validate their findings. They have also submitted a proposal for funding to confirm the molecular signature they identified by collaborating with a local dog trainer and comparing their technique’s results to those obtained with a canine nose. Depending on the outcome of these projects, Siegel and Agarwal say their test could become available to patients and doctors within the next few years. In the short-term, urine samples would have to be sent to a lab for analysis, but the researchers say their ultimate goal is to design a sensor that can yield results in a doctor’s office.
[osd_subscribe categories=’prostate-cancer’ placeholder=’Email Address’ button_text=’Subscribe Now for any new posts on the topic “PROSTATE CANCER”‘]
The Latest on: Prostate cancer
via Google News
The Latest on: Prostate cancer
- Telix APAC Report: Regulatory Progress for Prostate and Kidney Cancer Imagingon August 1, 2022 at 3:57 pm
Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today reports on regulatory progress for the Company's core prostate and kidney cancer imaging programs in the Asia Pacific (APAC) ...
- Tavanta Therapeutics Announces Completion of Enrollment in Pivotal Phase 3 Trial of TAVT-45 for the Treatment of Metastatic Prostate Canceron August 1, 2022 at 7:00 am
Tavanta Therapeutics, a clinical-stage specialty pharmaceutical company developing a diverse pipeline of specialty drugs that bring clinically meaningful benefits to patients with serious or ...
- Promising therapy if PSA rises after prostate cancer surgeryon July 31, 2022 at 9:24 pm
Research shows a promising new option for men who experience rising PSA after a radical prostatectomy. Many men who undergo surgical treatment for prostate cancer (a radical prostatectomy) live out ...
- Prostate Cancer Foundation fundraiser to raise awarenesson July 31, 2022 at 1:14 am
The Arkansas Prostate Cancer Foundation describes its new event -- Bourbon, Beards and Blue Ribbons -- as a night "celebrating the refined sites, sounds and tastes of the sophisticated adventurer." ...
- ADT Use for Prostate Cancer Linked to Increased Risk for CVD Deathon July 29, 2022 at 11:25 am
For patients with prostate cancer, use of androgen-deprivation therapy (ADT) is associated with an increased risk for cardiovascular disease (CVD) death, according to a study published online July 26 ...
- Study: Hormone therapy for prostate cancer may increase risk of deathon July 28, 2022 at 12:00 am
Hormone therapy is a common treatment option for prostate cancer, but it may increase the risk of death from heart disease, especially in older men, a new study finds.
- Pluvicto Approval Launches Theranostics in Prostate Canceron July 27, 2022 at 12:51 pm
Ashok Muthukrishnan, MD, MS, addresses the recent FDA approval of lutetium 177Lu vipivotide tetraxetan and looks to the potential of radioimmunotheranostics on the horizon.
- Prostate Cancer Treatment May Raise Heart Riskson July 27, 2022 at 8:47 am
Hormone therapy is a common treatment option for prostate cancer, but it may increase the risk of death from heart disease, especially in ...
- BAMF Health and Telix complete first total-body PET scans with Illuccix for prostate cancer imagingon July 27, 2022 at 5:39 am
The PSMA-PET  imaging agent Illuccix® from Telix Pharmaceuticals Limited (Telix) has been used in combination with the uEXPLORER®, a first-of-its kind total-body PET scanner from United Imaging for ...
via Bing News